key: cord-1002084-wbgx5k52
authors: Yeter, Duygu Yalinbas; Dursun, Demet; Bozali, Erman; Ozec, Ayse Vural; Erdogan, Haydar
title: Effects of the COVID-19 Pandemic on Neovascular Age-Related Macular Degeneration and Response to Delayed Anti-VEGF Treatment
date: 2021-02-10
journal: J Fr Ophtalmol
DOI: 10.1016/j.jfo.2021.02.001
sha: ffd9b6ce1433cb02f9cb62d08bdb9ec95494d904
doc_id: 1002084
cord_uid: wbgx5k52

Objectives:To investigate the effects of the COVID-19 pandemic on the treatment course of neovascular age-related macular degeneration (nAMD) patients who received anti-VEGF injection therapy with real-life data. Methods:This retrospective study consisted of 116 eyes of 106 patients. Ophthalmic examination, assessment of best-corrected visual acuity (BCVA), optical coherence tomography (OCT) findings and data of last two visits before restrictions (V-2 and V-1) and the first visit (V0) after the release of national lockdown and subsequent visits (V1 and Vlast) were recorded. The lockdown period was determined by the time interval between March 11 and June 1, 2020. Main results:The injection interval before V-1 was significantly longer than the interval after V0 (2.56±0.9 vs. 2.14±0.8 months, p=0.02). While the median central macular thickness (CMT) was significantly increased at V0 compared to V-1 [274(132-711) vs. 238(136-628), p<0.001], the median CMT was significantly lower at V1 compared to V0 [256 (136-591) vs. 274(132-711), p=0.003]. The median BCVA was 0.67(0.1-1.1) logMAR at V-1 and significantly worsened to 0.78 (0.1-1.2) logMAR at V0 (p=0.003). Although the median BCVA improved to 0.69 logMAR (0.1-1.2) at Vlast, the difference did not reach statistical significance compared to V0 (p=0.08). Conclusion:Treatment delay due to the COVID-19 pandemic cause progression of nAMD and visual impairment. To plan more frequent anti-VEGF treatments and visits may be an appropriate approach until the disease stabilizes. However, it should be kept in mind that despite the improvement in OCT findings, the desired success in VA could not be achieved in the short term.

Objectif: Étudier les effets de la pandémie de COVID-19 sur l'évolution du traitement des patients atteints de la forme néovasculaire de la dégénérescence maculaire liée à l'âge (DMLA) ayant reçu un traitement par injection anti-VEGF avec des données réelles. logMAR à V0 (p = 0,003). Bien que la MAVC médiane se soit améliorée à 0,69 logMAR (0,1-1,2) à Vlast, la différence n'a pas atteint une signification statistique par rapport à V0 (p = 0,08).

Conclusion: Le retard de traitement dû à la pandémie de COVID-19 entraîne une progression de la DMLA et une déficience visuelle. Planifier des traitements et des visites anti-VEGF plus fréquents peut être une approche appropriée jusqu'à ce que la maladie se stabilise. Cependant,

The novel coronavirus disease (COVID-19) caused by "severe acute respiratory syndrome coronavirus type 2" (SARS-CoV-2) primarily manifests as an acute upper and lower respiratory tract infection and could affect multiple organs and systems, including the heart, intestines, kidneys, blood, and nervous system. The disease's main way of transmission is especially by droplets and human-to-human direct contact [1] . Furthermore, SARS-CoV-2 was detected in tears, and conjunctival secretions of infected patients and the disease also showed ocular manifestations consisting of chemosis, epiphora, and conjunctival hyperemia [2] . The SERPICO-19 study has reported COVID-19 associated retinal findings such as hemorrhage, cotton wool spots, dilated veins, and tortuous vessels [3] . The total estimated frequency of severe cases and mortality were reported as 25% (17.4-34.9 ) and 3.6% (1.1-7.2), respectively, and COVID-19 was recognized as a pandemic by the World Health Organization (WHO) on March 11, 2020 [4] . The rapid and uncontrolled spread of the disease all around the world forced governments to lockdown cities, apply social distancing rules, cancel scientific meetings, and limit non-essential works [5] .

The American Academy of Ophthalmology (AAO) alerted ophthalmologists, health workers, and hospitals to manage their workflow, including surgeries, treatment modalities, and patient visit intervals, during the outbreak of COVID-19 to minimize the risk of infection transmission and prevent spread among patients and health workers [6] . They recommended eye protection, frequent and careful disinfection of clinics, and personal protective equipment such as face coverings [7] . As a part of daily ophthalmology practice, patients with retinal diseases are generally elderly and had multiple comorbid conditions, which could facilitate the morbidity and mortality of COVİD-19 disease [4] . However, retinal diseases, particularly proliferative diabetic retinopathy, diabetic macular edema, and neovascular age-related J o u r n a l P r e -p r o o f 5 macular degeneration (nAMD), mostly need anti-vascular endothelial growth factor (VEGF) injections for treatment and can cause permanent vision loss if left untreated [5] .

Age-related macular degeneration (AMD) is the leading cause of severe vision loss in people aged over 50 years [8] . Neovascular age-related macular degeneration, a late stage of the disease, is characterized by the development of macular neovascularization (MNV), which may be responsible for irreversible damage of photoreceptors and retinal pigment epithelium [9] . Macular neovascularization is a new terminology that is accepted instead of choroidal neovascularization in nAMD [10] . Anti-VEGF agents have been used as a gold standard treatment method in the nAMD to prevent disease progression and provide anatomical and functional improvement. However, it is crucial to apply the injections at appropriate intervals for the success of the treatment [11] .

During the ongoing outbreak of COVID-19, it has been an important challenge to manage patients with retinal diseases to prevent disease progression, avoid vision loss, and protect healthcare professionals and high-risk patients. For this purpose, different treatment algorithms and guidelines have been recommended by different clinics to continue applying intravitreal anti-VEGF injections for patients, particularly those with nAMD [5, 6, 12] .

However, restrictions (social distancing rules, lockdowns, curfews), increased anxiety levels of patients, and difficulty in accessing hospitals caused delays in treatment protocols.

In this study, we aimed to investigate the effects of the COVID-19 pandemic on the treatment course of nAMD patients who received anti-VEGF injection therapy with real-life data.

This retrospective study was conducted in the retina clinic of the Department of 

All patients were receiving "pro re nata" (PRN-"as needed") anti-VEGF treatment regimen in our clinical routine. "Pro re nata" therapy was performed after three consecutive monthly injections. All patients underwent a complete baseline ophthalmic examination, including intraocular pressure (IOP) measurement, assessment of best-corrected visual acuity (BCVA) measured by using a Snellen chart and converted to the logarithm of the minimum angle of resolution (logMAR), slit-lamp biomicroscopy, dilated fundus examination, and 7 spectral domain-optical coherence tomography (SD-OCT) imaging (Nidek RS-3000 Advance, Japan). We defined central macular thickness (CMT) as the mean retinal thickness in the central 1000 µm area. Additionally, exudative features of MNV as described before, including subretinal fluid (SRF), intraretinal fluid (IRF), and subretinal hyperreflective material (SRHM), were evaluated by three independent and experienced specialist [10] . We retrospectively collected the records of at least two previous visits (V-2 and V-1), which contains complete ophthalmology examinations before the restrictions. First visit after restrictions recorded as "V0" and the subsequent visits recorded as "V1" and "Vlast." V1 was described as the first visit after the first injection, and Vlast was determined as the last visit.

All patients included in the study with the V-2 visit consisted of patients who had completed the loading phase (at least three injections) of anti-VEGF treatment prior to the V-2 visit. In addition, the PRN treatment regimen was continued without a new three consecutive monthly injections protocol after V0 visit.

Demographic characteristics (age, gender) were recorded. Also, BCVA, CMT, and OCT findings for all visits (V-1, V-2, V0, V1, and Vlast), the total number of injections, type of anti-VEGF injections, and time interval between injections before V-1 and after V0 were evaluated. We also determined the associated factors with increased CMT and BCVA.

Additionally, the attendance rates in relation to visits and anti-VEGF treatments during the pandemic period were compared with the same dates of last year from the hospital records. logMAR at the last visit, the difference did not reach statistical significance compared to V0 (p=0.08) ( Figure 3B ). Linear logistic regression analysis showed that the time interval between V0 and V1 was associated with BCVA change (from Vlast to V0)

We anticipated deterioration in the course of the nAMD disease during the COVID-19 pandemic due to the delay in treatment. However, it was important to evaluate the real-life data to determine how much degradation might occur and how much recovery might be observed. In this study, we found an increase in CMT after releasing the restrictions, while it was in a downward trend before the pandemic. However, CMT showed significant The COVID-19 outbreak is a global crisis that affects and changes the world order, even causing more than one million death to date. In this period, the social lives of people have been restricted, the economic burden has increased, and perhaps the most important effect of the pandemic was delaying the diagnosis and treatment of chronic diseases that require regular follow-up. Thus, this situation creates difficulty for maintaining the balance between providing treatments for ocular diseases against the risk of cross-infection of COVID-19 between patients and healthcare staff [13] .

In developed countries, AMD is the major cause of legal blindness in the adult population. Neovascular AMD, one of the advanced forms of the disease, is characterized by MNV, which causes hemorrhage, fluid accumulation, and macular fibrosis [14] . The expression of VEGF is responsible for increased angiogenesis and vascular permeability.

Thus, effective treatment for nAMD is based on targeting VEGF inhibition [15] . Anti-VEGF agents, including bevacizumab, ranibizumab, and aflibercept, effectively limit progression and improve vision in nAMD patients [16] . However, the application of these agents at appropriate intervals is crucial to control the activation of the disease, prevent progression and improve vision. Studies on the optimal treatment regimen intervals are still ongoing. The monthly application of bevacizumab and ranibizumab and bimonthly application of aflibercept was specifically supported in initial studies [17] [18] [19] .

The higher number of injections may provide a better visual acuity but also causes an increase in the number of sight-threatening complications, such as endophthalmitis. In addition, more injections may lead to an economic burden for patients and increase healthcare costs. To reduce these disadvantages, different treatment regimens, such as quarterly, PRN (as needed), treat-and-extend, and observe-and-plan regimens, have been developed [20] . Despite Page 11 of 20 J o u r n a l P r e -p r o o f 11 these treatment algorithms, delay or discontinuation of treatment can lead to permanent visual loss due to progressive retinal pigment epithelium death and photoreceptor loss. While prompt treatment may provide less macular disruption, increasing delay duration may lead to irreversible changes in the macular anatomy. Lim et al. indicated that 21 weeks or longer treatment delays resulted in a 5-fold increased worsening of visual outcomes after treatment compared to a delay of 7 weeks or shorter between the first symptoms and their first anti-VEGF treatment [14] . Kim et al. reported an increasing deterioration in visual acuity at 6, 12, and 24 months after treatment discontinuation in nAMD patients who needed treatment but left the treatment [21] . Additionally, real-world studies confirmed that delay of active disease re-treatment could lead to worse visual outcomes and less reduction in central subfield macular thickness [22] . Furthermore, a higher CRT increase was found to be associated with visual acuity loss [23] . Our patients with active disease had approximately five months of treatment delay. Similar to real-life studies, there was a significant increase in CMT in our study at V0, and this increase may be responsible for worsening visual acuity.

On the other hand, we showed significant improvement in CMT and reached the before restriction period value within a short time with the start of the anti-VEGF injections, but we could not achieve a similar improvement in visual acuity. This may be explained by the fact that long-lasting damage to the photoreceptors and retinal pigment epithelium affects the visual prognosis more negatively, even if structural success is achieved. In a previous study, it was reported that a 23.5±10.4 day delay between anti-VEGF indication to treatment caused an increase in central retinal thickness (CRT) by 31.5 ±69.6 µm with VA loss (-2.2±5.0 letters) [24] . After the treatment initiation, they showed that CRT was regressed 47.7±117.5 µm with worse regain in VA (0.4±7.4 letters) [24] . They suggested that functional deterioration despite morphologic response to therapy is likely to be caused by the loss of photoreceptors.

outcomes of 112 eyes with nAMD [11] . They showed that delayed visits were significantly associated with worse structural and functional outcomes. Furthermore, increased exudative disease activity has also been shown, as we have demonstrated in our study. Various studies have demonstrated that the PRN regimen can provide comparable results to a fixed dosing regimen concerning visual acuity improvement, but it is important to provide prompt injections if needed [25] . Unfortunately, during this COVID-19 pandemic, patients could not receive the needed injections. Delayed or omitted injections have resulted in increased CMT, which leads to visual deterioration. In addition to the study mentioned above, we also evaluated the treatment effects after the lockdown period and found a regression in exudative features and disease activation during follow-up. Before the pandemic period, injection intervals were longer than intervals after V0. Starting anti-VEGF injections immediately after the restrictions were ended, and applying more frequent injections in a short time may lead to the regression of the disease activation and even more positive results. In previous studies, higher treatment frequency was reported associated with favorable outcomes [26] . lockdown [27] . In our study, newly developed submacular hemorrhages occurred in 7 patients, and the rate was higher from the study above. This may be explained by a further delay in our treatments and appointments.

Our study has some limitations. Firstly, our study population was heterogeneous, and this may be associated with a wide range in CMT, visual acuity, and injection numbers.

Secondly, follow up time after restrictions were short. This may be insufficient to predict the 

Treatment delay due to the COVID-19 pandemic caused the progression of the disease and the visual impairment in patients with nAMD. After treatment delay or discontinuation, to plan anti-VEGF treatment immediately and more frequent visit intervals may be appropriate until the disease stabilizes. However, it should be kept in mind that despite the improvement in CMT, the desired success in visual acuity could not be achieved in the short term. 

COVID-19 and the eye: how much do we really know? A best evidence review

Ocular manifestations and clinical characteristics of 534 cases of COVID-19 in China: A cross-sectional study

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis

Management of neovascular age-related macular degeneration during the COVID-19 pandemia

Proposed algorithm during COVID-19 pandemic for patient management in medical retina clinic

Update and Recommendations for Ocular Manifestations of COVID-19 in Adults and Children: A Narrative Review

Age-Related Macular Degeneration Is the Leading Cause of Blindness

Anatomical and functional changes in neovascular AMD in remission: comparison of fibrocellular and fibrovascular phenotypes

Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group

Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic

Treating neovascular age-related macular degeneration in the era of COVID-19. Graefe's Arch Clin Exp Ophthalmol: in press

Ophthalmology in the time of COVID-19: experience from Hong Kong Eye Hospital

Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration

Vascular endothelial growth factor a in intraocular vascular disease

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration

Ranibizumab for neovascular age-related macular degeneration

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration

Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review

Recent developments in age-related macular degeneration: a review

Natural course of patients discontinuing treatment for agerelated macular degeneration and factors associated with visual prognosis

Detrimental Effect of Delayed Retreatment of active disease on Outcomes in Neovascular Age Related Macular Degeneration-RAMPS Study

Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity

Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefe's Archive for

Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome

Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment

Increased Number of Submacular Hemorrhages As a Consequence of COVID-19 Lockdown